Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/25174
Title: Behavioural support and nicotine replacement therapy for smokeless tobacco cessation: protocol for a pilot randomised-controlled multi-country trial
Authors: Siddiqui, F
Bauld, L
Croucher, R
Jackson, C
Kellar, I
Kanaan, M
Pokhrel, S
Huque, R
Iqbal, R
Khan, JA
Mehrotra, R
Siddiqi, K
Keywords: tobacco;smokeless;tobacco use cessation;nicotine;Asia
Issue Date: 22-Aug-2022
Publisher: BMC (Springer Nature)
Citation: Siddiqui, F. et al. (2022) 'Behavioural support and nicotine replacement therapy for smokeless tobacco cessation: protocol for a pilot randomised-controlled multi-country trial', Pilot and Feasibility Studies, 8 (1), 189, pp. 1-12. doi: 10.1186/s40814-022-01146-5.
Abstract: Copyright © The Author(s) 2022. Background: Smokeless tobacco (ST) is consumed globally by more than 350 million people, with approximately 85% of all users based in South and Southeast Asia. In this region, ST products are cheap and easily accessible. Evidence-based interventions to people quit ST use are lacking. This study aims to test the feasibility of conducting a future definitive trial of ST cessation, using a culturally adapted behavioural intervention, and/or nicotine replacement therapy (NRT) in three South Asian countries. Methods: We will conduct a factorial design, randomised-controlled pilot trial in Bangladesh, India and Pakistan. Daily ST users will be recruited from primary health care settings in Dhaka, Noida and Karachi. Participants will be individually randomised to receive intervention A (4 or 6 mg NRT chewing gum for 8-weeks), intervention B (BISCA: face-to-face behavioural support for ST cessation), a combination of interventions A and B or usual care (Very Brief Advice - VBA). The participants will provide demographic and ST use related data at baseline, and at 6, 12 and 26 weeks of follow-up. Salivary cotinine samples will be collected at baseline and 26 weeks. The analyses will undertake an assessment of the feasibility of recruitment, randomisation, data collection and participant retention, as well as the feasibility of intervention delivery. We will also identify potential cessation outcomes to inform the main trial, understand the implementation, context and mechanisms of impact through a process evaluation and, thirdly, establish health resource use and impact on the quality of life through health economic data. Discussion: The widespread and continued use of ST products in South Asia is consistent with a high rate of associated diseases and negative impact on the quality of life. The identification of feasible, effective and cost-effective interventions for ST is necessary to inform national and regional efforts to reduce ST use at the population level. The findings of this pilot trial will inform the development of larger trials for ST cessation among South Asian users, with relevance to wider regions and populations having high rates of ST use. Trial registration: ISRCTN identifier 65109397
Description: Availability of data and materials: Not applicable.
Supplementary Information: Additional file 1. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents, available at https://ndownloader.figstatic.com/files/36767631
URI: https://bura.brunel.ac.uk/handle/2438/25174
DOI: https://doi.org/10.1186/s40814-022-01146-5
Other Identifiers: 189
Appears in Collections:Dept of Health Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © The Author(s) 2022. Rights and permissions: Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.1.42 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons